• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avalon GloboCare Expands AI Product Portfolio with Planned Launch of Beacon, an Agentic Generative Engine Optimization Platform for Small Businesses

    7/15/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALBT alert in real time by email

    FREEHOLD, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology innovation company developing products for high-growth health and technology markets, a developer of agentic artificial intelligence ("AI") software solutions, today announced plans to launch Beacon, a subscription-based Agentic Generative Search Optimization (GEO) platform designed to help small businesses improve their visibility across leading AI-powered search engines. The Company currently expects Beacon to launch commercially in late Q3 2026.

    Beacon represents the second software product within Avalon's growing portfolio of agentic AI applications and represents another step in the Company’s strategy to build scalable Software-as-a-Service ("SaaS") businesses focused on generating recurring subscription revenue. Beacon will complement Catch-Up™, Avalon’s AI-powered short-form agentic video studio platform, which is currently undergoing Phase 2 development.

    As consumers increasingly rely on AI-powered search engines such as ChatGPT, Gemini, Claude, Perplexity, and Grok to recommend products and services, businesses face a new challenge: ensuring they are visible within AI-generated recommendations rather than traditional search rankings. According to a recent report published by McKinsey & Company, approximately 50% of consumers now use AI-powered search to make purchasing decisions, while nearly 60% of searches end without users clicking through to a website because AI-generated responses increasingly provide direct answers and recommendations.

    Beacon is designed to help address this emerging market by autonomously analyzing a company's AI search visibility and generating implementation-ready recommendations to improve its presence across leading AI-powered search engines.

    The platform is expected to autonomously:

    • Diagnose a business's AI visibility in approximately 60 seconds;
    • Generate a competitive gap analysis and optimization recommendations; and
    • Produce implementation-ready agent services on an ongoing basis.



    Beacon is expected to be offered through a recurring monthly SaaS subscription model, providing customers with continuous AI visibility monitoring, optimization recommendations, and ongoing content, reputation and engagement agent services.

    In addition to the core subscription offering, customers will have the option to engage Avalon under separate services agreements to implement Beacon's AI-generated recommendations.

    "We believe AI-powered search is fundamentally changing how consumers discover businesses online," said Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. "As AI-generated answers increasingly replace traditional search results, businesses need entirely new tools to remain visible. Beacon is designed to help address this emerging challenge through an autonomous platform that analyzes AI visibility, identifies opportunities, and generates implementation-ready recommendations."

    Beacon complements Avalon’s broader AI software strategy, which also includes the Catch-Up™ platform. Currently in Phase 2 development, Catch-Up is being transformed into a fully autonomous, agentic AI-powered content creation platform through Avalon’s previously announced collaboration with Caylent, Inc., an Amazon Web Services (AWS) Premier Tier Consulting Partner. Upon completion, Catch-Up is expected to expand beyond podcast creators to serve social media influencers, marketers, brands, and e-commerce businesses, significantly increasing its addressable market.

    "Together, Beacon and Catch-Up reflect our strategy of building scalable, subscription-based agentic AI software platforms addressing large and growing commercial markets," added Meng Li. "We believe these products position Avalon to capitalize on the accelerating adoption of agentic AI while creating multiple opportunities for recurring software and services revenue."

    About Avalon GloboCare Corp.

    Avalon GloboCare Corp. (NASDAQ:ALBT) is a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets. Through its wholly-owned subsidiary, Avalon Quantum AI LLC, the Company is advancing next-generation Agentic AI systems, including automated video generation, and small business marketing. Avalon is also distributing the KetoAir™ breathalyzer device a non-invasive consumer breathalyzer that measures ketosis levels and is sold in North America, which is registered with the U.S. Food and Drug Administration as a Class I medical device.

    For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

    Forward-Looking Statements

    Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "should", "may", and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

    Contact Information:

    Avalon GloboCare Corp.

    4400 Route 9 South, Suite 3100

    Freehold, NJ 07728

    PR@Avalon-GloboCare.com

    Investor Relations:

    Crescendo Communications, LLC

    Tel: (212) 671-1020 Ext. 304

    albt@crescendo-ir.com



    Primary Logo

    Get the next $ALBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lu Wenzhao

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:33:21 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sanders Steven Andrew

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:33:01 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mathews Michael

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:31:24 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    SEC Filings

    View All

    Avalon GloboCare Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Change Agents Corporation. (0001630212) (Filer)

    7/21/26 8:45:13 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEL AM filed by Avalon GloboCare Corp.

    DEL AM - Avalon GloboCare Corp. (0001630212) (Filer)

    7/13/26 4:57:05 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-1 filed by Avalon GloboCare Corp.

    S-1 - Avalon GloboCare Corp. (0001630212) (Filer)

    7/10/26 7:29:07 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalon GloboCare Announces Strategic Transformation into Agentic AI Software Company; Rebrands as Change Agents Corp.

    Company to begin trading tomorrow under new Nasdaq ticker symbol CHGA as it advances its portfolio of agentic AI software platforms, including Beacon and Catch-Up Company is actively evaluating additional AI software opportunities in other sectors such as defense and security FREEHOLD, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of agentic artificial intelligence ("AI") software solutions, today announced its strategic transformation into an agentic artificial intelligence software company focused on developing agentic AI software-as-a-service (SaaS) applications. In connection with this transformation, the Company

    7/21/26 8:30:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon GloboCare Expands AI Product Portfolio with Planned Launch of Beacon, an Agentic Generative Engine Optimization Platform for Small Businesses

    FREEHOLD, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology innovation company developing products for high-growth health and technology markets, a developer of agentic artificial intelligence ("AI") software solutions, today announced plans to launch Beacon, a subscription-based Agentic Generative Search Optimization (GEO) platform designed to help small businesses improve their visibility across leading AI-powered search engines. The Company currently expects Beacon to launch commercially in late Q3 2026. Beacon represents the second software product within Avalon's growing portfolio of agentic AI applications and repr

    7/15/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program

    FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today provided an update on the Nevada POOL/PACT Holistic Health Reset program launched in collaboration with Saga Health and SpecialtyHealth, Inc. The four-month wellness initiative, which began in August 2025, was designed to support 50 first responders through a comprehensive health optimization program focused on improving metabolic, physical, and behavioral wellness outcomes. Participants in the program are util

    6/16/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Financials

    Live finance-specific insights

    View All

    Avalon GloboCare Acquires RPM Interactive, a Generative AI Software Company, in an All-Stock Transaction

    Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders' equity deficiency RPM Interactive has developed a fully automated, generative AI powered SaaS platform for creating short-form video content FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of precision diagnostic consumer products, today announced that it has acquired RPM Interactive, Inc. ("RPM"), a generative artificial intelligence ("AI") publishing and software company, in an all-stock transaction. As a result of the acquisition, the Company believes it

    12/15/25 8:30:00 AM ET
    $ALBT
    $ASPU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Consumer Discretionary

    Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

    FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired Merlin Medical Supply ("MMS"), a profitable, well-established Home Medical Equipment ("HME") and Durable Medical Equipment ("DME") company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontine

    9/13/23 9:15:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

    FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired DE Laboratory LLC ("DE Labs"), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company. Avalon owns a 40% interest in LSM. DE Labs is a CLIA-certified and COLA-accredited laboratory located in Houston, Texas that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing. LSM is no

    7/24/23 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Leadership Updates

    Live Leadership Updates

    View All

    Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer

    FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced the appointment of Sam Knipper as Chief Financial Officer, effective June 1, 2026. Mr. Knipper succeeds Luisa Ingargiola, who has served as the Company's Chief Financial Officer since February 2017 and has been appointed as Chief Strategy Officer, where she will continue supporting the Company's long-term strategic initiatives, capital markets activities, and growth opportunities. Mr. Knipper brings

    6/4/26 8:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

    DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ:HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the appointment of Luisa Ingargiola to its Board of Directors, effective February 24, 2025. Ms. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain a member of the Board. She will also serve as a member of the Nominating Committee, Audit Committee, and Compensation Committee. Following Ms. Ingargiola's appointment, the Board will be comprised of six directors, four of whom have been determined by the Board to be "independent directors" under

    2/27/25 8:00:00 AM ET
    $ALBT
    $HTOO
    $VMAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Energy

    Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

    FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epid

    10/31/24 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care